AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33779799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower birthweight
Number of subjects: 66
Study 33779799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors (GA, birthweight, PMA, sex, race, multiparity, maximum ROP stage, OCT features)
Number of subjects: 66
Study 33779850 — intervention group
Group type: EXPERIMENTAL
Intervention: Side lying position
Number of subjects: 12
Study 33779850 — intervention group
Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 12
Study 33779850 — intervention group
Group type: COMPARATOR
Intervention: Squatting position
Number of subjects: 12
Study 33779887 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline cardiovascular fitness
Number of subjects: 543
Study 33779887 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline muscular strength
Number of subjects: 543
Study 33779887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and/or strength training interventions
Number of subjects: 543
Study 33779887 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy completion (RDI ≥ 85%)
Number of subjects: 543
Study 33779986 — intervention group
Group type: COMPARATOR
Intervention: Heparin versus no treatment/placebo
Number of subjects: 3839
Study 33779986 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH versus UFH
Number of subjects: 3839
Study 33779986 — intervention group
Group type: COMPARATOR
Intervention: UFH versus no treatment
Number of subjects: 3839
Study 33779986 — intervention group
Group type: COMPARATOR
Intervention: Heparin versus placebo
Number of subjects: 3839
Study 33779986 — intervention group
Group type: COMPARATOR
Intervention: LMWH versus no treatment/placebo
Number of subjects: 3839
Study 33780567 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose, long-acting intravenous dalbavancin
Number of subjects: 309
Study 33780567 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 309
Study 33780662 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib 80 mg orally once daily
Number of subjects: 220
Study 33781087 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding as an infant
Number of subjects: 0
Study 33781087 — intervention group
Group type: COMPARATOR
Intervention: Not breastfed as an infant
Number of subjects: 0
Study 33781352 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Decision Skills Training (CDST)
Number of subjects: 0
Study 33781352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation Resource Team process
Number of subjects: 0
Study 33781677 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoreflex NC scoring angioplasty catheter
Number of subjects: 200
Study 33781934 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring tool for systemic symptoms during aspirin challenge
Number of subjects: 0
Study 33781957 — intervention group
Group type: EXPERIMENTAL
Intervention: LMC-based Fizyosoft® HandROM System
Number of subjects: 35
Study 33781957 — intervention group
Group type: COMPARATOR
Intervention: Universal goniometer
Number of subjects: 35
Study 33781988 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion targets
Number of subjects: 0
Study 33781988 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33782021 — intervention group
Group type: COMPARATOR
Intervention: Occupations characterised by being mostly sedentary (ISCO group 1-4)
Number of subjects: 11474
Study 33782021 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupations with primarily physical demanding work (ISCO group 5-9)
Number of subjects: 11474
Study 33782021 — intervention group
Group type: EXPERIMENTAL
Intervention: Female workers
Number of subjects: 11474
Study 33782211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Irradiation (GI) at a target dose of 50 kGy
Number of subjects: 48
Study 33782211 — intervention group
Group type: COMPARATOR
Intervention: Non-Gamma Irradiation (non-GI)
Number of subjects: 48
Study 33782300 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1
Study 33782300 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study 33782310 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1
Study 33782310 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up 68Ga-FAPI PET/CT
Number of subjects: 1
Study 33782310 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study 33782906 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (adapted)
Number of subjects: 49
Study 33782906 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial discrimination (group-level)
Number of subjects: 49
Study 33782906 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial identity-centrality (among NHB women)
Number of subjects: 49
Study 33782940 — intervention group
Group type: COMPARATOR
Intervention: Any weight loss intervention
Number of subjects: 988
Study 33782940 — intervention group
Group type: COMPARATOR
Intervention: Surgical interventions
Number of subjects: 988
Study 33782940 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical weight loss interventions
Number of subjects: 988
Study 33782956 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (XOLAIR) from baseline to week 16 and mOIT from week 8 to week 36
Number of subjects: 0
Study 33782956 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33783067 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (150 mg/m²) and temozolomide
Number of subjects: 55
Study 33783145 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered wearable exoskeleton (H-MEX) training, 60 minutes, 3 times per week for 10 weeks (total 30 sessions)
Number of subjects: 10
Study 33783145 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered wearable exoskeleton (H-MEX) training
Number of subjects: 10
Study 33783269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for COVID-19-associated respiratory failure
Number of subjects: 32
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-salt diet (3.0 g/day)
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high-salt diet (18 g/day)
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs12042763
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2861813
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs2294654
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs718067
Number of subjects: 80
Study 33783375 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based analysis of Pappa2
Number of subjects: 80
Study 33783425 — intervention group
Group type: EXPERIMENTAL
Intervention: TRM program intervention
Number of subjects: 2104
Study 33783425 — intervention group
Group type: COMPARATOR
Intervention: Purgative containing polyethylene glycol
Number of subjects: 2104
Study 33783425 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 2104
Study 33783498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (200, 500, 700, and 1000 mg single intravenous dose)
Number of subjects: 24
Study 33783586 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal late-pregnancy consumption of gluten-containing foods
Number of subjects: 8556
Study 33783586 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal late-pregnancy consumption of selected foods (non-gluten cereals, fresh milk, sour milk, cheese products, soy products, lean/medium-fat fish, fatty fish)
Number of subjects: 8556
Study 33783586 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gluten-containing food consumption by country
Number of subjects: 8556
Study 33783691 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaco criteria
Number of subjects: 40
Study 33783691 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM criteria
Number of subjects: 40
Study 33783815 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 158
Study 33783815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 158
Study 33783955 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 11140
Study 33783955 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anxiety/depression
Number of subjects: 11140
Study 33783955 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, higher total cholesterol, HbA1c, waist circumference, waist-to-height ratio, moderately increased albumin-creatinine ratio, stroke/transient ischaemic attack, and retinal disease
Number of subjects: 11140
Study 33783955 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher years at education completion, baseline cognitive function, taller stature, and current alcohol use
Number of subjects: 11140
Study 33783955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in risk factors
Number of subjects: 11140
Study 33784265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1252
Study 33784265 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 1252
Study 33784394 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week vegan diet
Number of subjects: 23
Study 33784416 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 3851
Study 33784963 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fixed citrate concentration protocol (fixed protocol)
Number of subjects: 66
Study 33784963 — intervention group
Group type: COMPARATOR
Intervention: Titrated protocol (historical control)
Number of subjects: 66
Study 33785064 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic intervention including information, consultation, and networking components.
Number of subjects: 100
Study 33785064 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study 33785220 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Test positive
Number of subjects: 254
Study 33785220 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Test
Number of subjects: 254
Study 33785324 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytochemical-enriched low-nitrite meat diet
Number of subjects: 63
Study 33785324 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry diet
Number of subjects: 63
Study 33785324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-enriched water
Number of subjects: 63
Study 33785324 — intervention group
Group type: COMPARATOR
Intervention: Conventional processed meats and low-nitrite processed meat diets
Number of subjects: 63
Study 33785483 — intervention group
Group type: EXPERIMENTAL
Intervention: SINE compounds in combination with R-CHOP
Number of subjects: 0
Study 33785483 — intervention group
Group type: EXPERIMENTAL
Intervention: SINE compounds
Number of subjects: 0
Study 33785489 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1: Enhanced provision
Number of subjects: 226
Study 33785489 — intervention group
Group type: COMPARATOR
Intervention: Model 2: Independent provision
Number of subjects: 226
Study 33785489 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 226
Study 33785495 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with persistent symptoms following recovery from acute SARS-CoV-2 infection
Number of subjects: 201
Study 33785495 — intervention group
Group type: COMPARATOR
Intervention: Hospitalisation
Number of subjects: 201
Study 33785495 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe post-COVID-19 syndrome
Number of subjects: 201
Study 33785495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild organ impairment
Number of subjects: 201
Study 33785590 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study 33785590 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAM-1 expression
Number of subjects: 0
Study 33785590 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical imaging and PET using near-infrared fluorescence dye
Number of subjects: 0
Study 33785610 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 112
Study 33785784 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNAemia (RNAemia) defined as RNA copies above 1000/ml measured by PCR in plasma
Number of subjects: 92
Study 33785784 — intervention group
Group type: COMPARATOR
Intervention: Patients without RNAemia
Number of subjects: 92
Study 33786329 — intervention group
Group type: COMPARATOR
Intervention: Low-Molecular Weight Hyaluronic Acid (LMW-HA); n = 14; 3 weekly intra-articular injections.
Number of subjects: 34
Study 33786329 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP); n = 19; 3 weekly intra-articular injections.
Number of subjects: 34
Study 33786329 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-PRP
Number of subjects: 34
Study 33786412 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-4000, a recombinant yeast expressing mutated RAS proteins
Number of subjects: 0
Study 33786412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33786454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 1090
Study 33786454 — intervention group
Group type: COMPARATOR
Intervention: No Rituximab
Number of subjects: 1090
Study 33786517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal intervention for menopause
Number of subjects: 0
Study 33786515 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33786522 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 0
Study 33786583 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (Duv) and Venetoclax (Ven) combination
Number of subjects: 4
Study 33786583 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (Duv)
Number of subjects: 4
Study 33786583 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (Ven)
Number of subjects: 4
Study 33786583 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study 33786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision devices
Number of subjects: 4812
Study 33786812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus glucocorticoid
Number of subjects: 104
Study 33786812 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid alone
Number of subjects: 104
Study 33786851 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels (continuous covariate)
Number of subjects: 9323
Study 33786851 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C levels (fourth quartile)
Number of subjects: 9323
Study 33787078 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG20 plus low-dose cytarabine (LDC)
Number of subjects: 0
Study 33787078 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDC)
Number of subjects: 0
Study 33787290 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTRA-ACS
Number of subjects: 13192
Study 33787290 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART pathway
Number of subjects: 13192
Study 33787290 — intervention group
Group type: COMPARATOR
Intervention: HEART score, Emergency Department Assessment of Chest Pain Score Accelerated Diagnostic Protocol, troponin-only strategies, unstructured physician gestalt
Number of subjects: 13192
Study 33787401 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-selective intra-arterial indocyanine green (ICG) administration (5 mL bolus at .125 mg/mL)
Number of subjects: 8
Study 33787401 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-selective intra-arterial indocyanine green (ICG) administration
Number of subjects: 8
Study 33787530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training after 14 days of immobilization
Number of subjects: 1
Study 33787530 — intervention group
Group type: COMPARATOR
Intervention: Immobilization for 14 days
Number of subjects: 1
Study 33787530 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessment during rest and submaximal exercise
Number of subjects: 1
Study 33787565 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine complete blood count (CBC) on the first postoperative day
Number of subjects: 570
Study 33788415 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase
Number of subjects: 0
Study 33788415 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) atezolizumab
Number of subjects: 0
Study 33788611 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Interventions
Number of subjects: 0
Study 33788611 — intervention group
Group type: COMPARATOR
Intervention: Pain Medication
Number of subjects: 0
Study 33788646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic breast surgery
Number of subjects: 0
Study 33788646 — intervention group
Group type: COMPARATOR
Intervention: Conventional breast conserving surgery
Number of subjects: 0
Study 33789265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endexo dialyzer
Number of subjects: 41
Study 33789265 — intervention group
Group type: COMPARATOR
Intervention: Optiflux dialyzer
Number of subjects: 41
Study 33789592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 0
Study 33789592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 0
Study 33789592 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 33789635 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results, and microbiota analysis.
Number of subjects: 300
Study 33789635 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data.
Number of subjects: 300
Study 33789643 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restorative cavity control (NRCC) through cavity enlargement using metallic sandpaper
Number of subjects: 148
Study 33789643 — intervention group
Group type: COMPARATOR
Intervention: Resin composite restorations (RCR)
Number of subjects: 148
Study 33789643 — intervention group
Group type: EXPERIMENTAL
Intervention: NRCC
Number of subjects: 148
Study 33789643 — intervention group
Group type: COMPARATOR
Intervention: RCR
Number of subjects: 148
Study 33789701 — intervention group
Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in PAH patients
Number of subjects: 150
Study 33789701 — intervention group
Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in rTOF patients
Number of subjects: 150
Study 33789701 — intervention group
Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in rTOF and PAH patients
Number of subjects: 150
Study 33789723 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) as destination therapy
Number of subjects: 16
Study 33789739 — intervention group
Group type: EXPERIMENTAL
Intervention: PAIN
Number of subjects: 76
Study 33789739 — intervention group
Group type: COMPARATOR
Intervention: PubMed
Number of subjects: 76
Study 33789756 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO-closure in high-risk PFO patients ≤60 years (n=103)
Number of subjects: 236
Study 33789756 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO-closure in high-risk PFO patients >60 years (n=43)
Number of subjects: 236
Study 33789855 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnostic assessments (EDA) using echocardiograms performed in the third week of age and at 32 weeks PMA.
Number of subjects: 350
Study 33789855 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined echocardiographic markers including pulmonary artery acceleration time and tricuspid annular plane systolic excursion.
Number of subjects: 350
Study 33789855 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic assessment (SDA) for cPH at 36 weeks PMA.
Number of subjects: 350
Study 33790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 173
Study 33790041 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 173
Study 33790560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (with insomnia, N=78)
Number of subjects: 299
Study 33790560 — intervention group
Group type: COMPARATOR
Intervention: Group B (without insomnia, N=221)
Number of subjects: 299
Study 33790605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Fat Area (VFA) measurement
Number of subjects: 1017
Study 33790605 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off value of VFA
Number of subjects: 1017
Study 33790783 — intervention group
Group type: EXPERIMENTAL
Intervention: TangWang Prescription
Number of subjects: 0
Study 33790783 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33790833 — intervention group
Group type: EXPERIMENTAL
Intervention: Two exergame and two regular training sessions/week
Number of subjects: 63
Study 33790833 — intervention group
Group type: EXPERIMENTAL
Intervention: One exergame and one regular training session/week
Number of subjects: 63
Study 33790833 — intervention group
Group type: COMPARATOR
Intervention: Two regular training sessions/week
Number of subjects: 63
Study 33790833 — intervention group
Group type: COMPARATOR
Intervention: One regular training session/week
Number of subjects: 63
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: S-osteoglycin levels in T1D patients
Number of subjects: 190
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: S-osteoglycin levels in T2D patients
Number of subjects: 190
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with age, gender, microvascular complications, HbA1c, or plasma glucose in T1D patients
Number of subjects: 190
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with age, gender, microvascular complications, HbA1c, or plasma glucose in T2D patients
Number of subjects: 190